A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom

MYPI1999002465A0Inactive Publication Date: 1999-12-24
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI1999002465
Authority / Receiving Office
MY · MY
Patent Type
Applications
Priority Date
1998-06-24
Filing Date
1999-06-16
Publication Date
1999-12-24
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for anxiety and convulsions often have sedative side effects due to their action on GABAa receptors, and there is a lack of selective agonists or antagonists for specific subunits, limiting their therapeutic efficacy and specificity.

Method used

Development of substituted triazolo-pyridazine derivatives that act as selective ligands for GABAa receptors, particularly targeting the a2 and a3 subunits with high affinity and functional selectivity, reducing sedation propensity and enhancing anxiolytic and anticonvulsant effects.

Benefits of technology

The compounds demonstrate anxiolytic activity with reduced sedation, potentiate GABA EC20 response, and exhibit anticonvulsant properties by blocking seizures, while being capable of crossing the blood-brain barrier for effective oral administration.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

THERE IS DISCLOSED A COMPOUND SELECTED FROM 7-(1,1-DIMETHYLETHY)-6-(2-ETHYL-2H-1,2,4-TRIAZOL-3-YLMETHOXY)-3-(2-FLUOROPHENYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE OF FORMULA IA ; AND 7-CYCLOBUTYL-3-(2,6-DIFLUOROPHENYL)-6-(2-METHYL-2H-1,2,4-TRIAZOL-3-YLMETHOXY)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE, OF FORMULA IB:FIG. IA & FIG. IB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.THEY ARE SELECTIVE LIGANDS FOR GABAA RECEPTORS, IN PARTICULAR HAVING HIGH AFFINITY FOR THE (ALPHA)2 AND / OR (ALPHA)3 SUBUNIT THEREOF, AND ARE ACCORDINGLY OF BENEFIT IN THE TREATMENT AND / OR PREVENTION OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM, INCLUDING ANXIETY AND CONVULSIONS.FIG. 1
Need to check novelty before this filing date? Find Prior Art

Description

A SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVE, PHARMACEUTICAL COMPOSITIONS MADE THEREFROMThe present invention relates to substituted triazolo-pyridazine derivatives and to their use in therapy. More particularly, this invention is concerned with particular substituted l,2,4-triazolo[4,3-fc]pyridazine derivatives which are GABAa receptor ligands and are therefore useful in the therapy of deleterious mental states.Receptors for the major inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), are divided into two main classes: (1) GABAa receptors, which are members of the ligand-gated ion channel superfamily; and (2) GABAb receptors, which may be members of the G-protein linked receptor superfamily. Since the first cDNAs encoding individual GABAa receptor subunits were cloned the number of known members of the mammalian family has grown to include at least six a subunits, four p subunits, three y subunits, one 8 subunit, one £ subunit and two p subunits.Although knowledge of the diversity of the GABAa receptor gene family represents a huge step forward in our understanding of this ligand-gated ion channel, insight into the extent of subtype diversity is still at an early stage. It has been indicated that an a subunit, a p subunit and a y subunit constitute the minimum requirement for forming a fully functional GABAa receptor expressed by transiently transfecting cDNAs into cells. As indicated above, 8, e and p subunits also exist, but are present only to a minor extent in GABAa receptor populations.Studies of receptor size and visualisation by electron microscopy conclude that, like other members of the ligand-gated ion channel family, the native GABAa receptor exists in pentameric form. The selection of at least one a, one P and one y subunit from a repertoire of seventeen allows for the possible existence of more than 10,000 pentameric subunit combinations. Moreover, this calculation overlooks the additionalpermutations that would be possible if the arrangement of subunits around the ion channel had no constraints (i.e. there could be 120 possible variants for a receptor composed of five different subunits).Receptor subtype assemblies which do exist include, amongst many others, ocip2y2, a2p2 / 3y2, a3py2 / 3, a2pyl, a5p3y2 / 3, a6Py2, a6p5 and a4p5. Subtype assemblies containing anal sub unit are present in most areas of the brain and are thought to account for over 40% of GABAa receptors in the rat. Subtype assemblies containing a2 and a3 subunits respectively are thought to account for about 25% and 17% of GABAa receptors in the rat. Subtype assemblies containing an a5 subunit are expressed predominantly in the hippocampus and cortex and are thought to represent about 4% of GABAa receptors in the rat.A characteristic property of all known GABAa receptors is the presence of a number of modulatory sites, one of which is the benzodiazepine (BZ) binding site. The BZ binding site is the most explored of the GABAa receptor modulatory sites, and is the site through which anxiolytic drugs such as diazepam and temazepam exert their effect. Before the cloning of the GABAa receptor gene family, the benzodiazepine binding site was historically subdivided into two subtypes, BZl and BZ2, on the basis of radioligand binding studies. The BZl subtype has been shown to be pharmacologically equivalent to a GABAa receptor comprising the al subunit in combination with a p subunit and y2. This is the most abundant GABAa receptor subtype, and is believed to represent almost half of all GABAa receptors in the brain.Two other major populations are the oc2Py2 and oc3Py2 / 3 subtypes. Together these constitute approximately a further 35% of the total GABAa receptor repertoire. Pharmacologically this combination appears to be equivalent to the BZ2 subtype as defined previously by radioligand binding, although the BZ2 subtype may also include certain a5-containing subtype assemblies. The physiological role of these subtypes has hithertobeen unclear because no sufficiently selective agonists or antagonists were known.It is now believed that agents acting as BZ agonists at aipy2, a2Py2 or a3Py2 subunits will possess desirable anxiolytic properties. Compounds which are modulators of the benzodiazepine binding site of the GABAa receptor by acting as BZ agonists are referred to hereinafter as "GABAa receptor agonists". The al-selective GABAa receptor agonists alpidem and Zolpidem are clinically prescribed as hypnotic agents, suggesting that at least some of the sedation associated with known anxiolytic drugs which act at the BZ1 binding site is mediated through GABAa receptors containing the al subunit. Accordingly, it is considered that GABAa receptor agonists which interact more favourably with the a2 and / or a3 subunit than with al will be effective in the treatment of anxiety with a reduced propensity to cause sedation. Also, agents which are antagonists or inverse agonists at al might be employed to reverse sedation or hypnosis caused by al agonists.The compounds of the present invention, being selective ligands for GABAa receptors, are therefore of use in the treatment and / or prevention of a variety of disorders of the central nervous system. Such disorders include anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic and acute stress disorder, and generalized or substance-induced anxiety disorder; neuroses; convulsions; migraine; depressive or bipolar disorders, for example single-episode or recurrent major depressive disorder, dysthymic disorder, bipolar I and bipolar II manic disorders, and cyclothymic disorder; psychotic disorders including schizophrenia; neurodegeneration arising from cerebral ischemia; attention deficit hyperactivity disorder; and disorders of circadian rhythm, e.g. in subjects suffering from the effects of jet lag or shift work.Further disorders for which selective ligands for GABAa receptors may be of benefit include pain and nociception; emesis, including acute, delayed and anticipatory emesis, in particular emesis induced by chemotherapy or radiation, as well as post-operative nausea and vomiting; eating disorders including anorexia nervosa and bulimia nervosa; premenstrual syndrome; muscle spasm or spasticity, e.g. in paraplegic patients; and hearing loss. Selective ligands for GABAa receptors may also be effective as pre-medication prior to anaesthesia or minor procedures such as endoscopy, including gastric endoscopy.WO 98 / 04559 describes a class of substituted and 7,8-ring fused 1,2,4-triazolo[4,3-6]pyridazine derivatives which are stated to be selective ligands for GABAa receptors beneficial in the treatment and / or prevention of neurological disorders including anxiety and convulsions.The present invention provides certain triazolo-pyridazine derivatives, and pharmaceutical^ acceptable salts thereof, which possess desirable binding properties at various GABAa receptor subtypes. The compounds in accordance with the present invention have good affinity as ligands for the a2 and / or a3 subunit of the human GABAa receptor. The compounds of this invention interact more favourably with the a2 and / or a3 subunit than with the al subunit. Indeed, the compounds of the invention exhibit functional selectivity in terms of a selective efficacy for the a2 and / or a3 subunit relative to the al subunit.The compounds of the present invention are GABAa receptor subtype ligands having a binding affinity (Ki) for the a2 and / or a3 subunit, as measured in the assay described hereinbelow, of less than 1 nM. Furthermore, the compounds in accordance with this invention exhibit functional selectivity in terms of a selective efficacy for the a2 and / or a3 subunit relative to the al subunit. Moreover, the compounds according to the present invention possess interesting pharmacokinetic properties, notably in terms of improved oral bioavailability.The present invention provides a compound selected from 7-(l,l-dimethylethyl)-6-(2-ethyl-2i / -l,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-l,2,4-triazolo[4,3-6]pyridazine of formula IA; and 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-l,2,4-triazol-3-ylmethoxy)-l,2,4-triazolo[4,3-6]pyridazine of formula IB:and pharmaceutically acceptable salts thereof.The compounds in accordance with the present invention are encompassed within the generic scope of WO 98 / 04559. There is, however, no specific disclosure therein of the compound either of formula IA or of formula IB as depicted above, or pharmaceutically acceptable salts thereof.For use in medicine, the salts of the compounds of formula IA and IB above will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of a compound of formula IA or IB or of its pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of formula IA and IB include acid addition salts which may, for example, be formed by mixing a solution of a compound of formula IA or IB with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.Also provided by the present invention is a method for the treatment and / or prevention of anxiety which comprises administering to a patient in need of such treatment an effective amount of the compound of formula IA or IB as depicted above or a pharmaceutically acceptable salt thereof.Further provided by the present invention is a method for the treatment and / or prevention of convulsions (e.g. in a patient suffering from epilepsy or a related disorder) which comprises administering to a patient in need of such treatment an effective amount of the compound of formula IA or IB as depicted above or a pharmaceutically acceptable salt thereof.The binding affinity (Ki) of the compounds according to the present invention for the a3 subunit of the human GABAa receptor is conveniently as measured in the assay described hereinbelow. The a3 subunit binding affinity (Ki) of the compounds of the invention is less than 1 nM.The compounds according to the present invention elicit a selective potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the a3 subunit of the human GABAa receptor relative to the potentiation of the GABA EC20 response elicited in stably transfected recombinant cell lines expressing the al subunit of the human GABAa receptor.The potentiation of the GABA EC20 response in stably transfected cell lines expressing the a3 and al subunits of the human GABAa receptor can conveniently be measured by procedures analogous to the protocol described in Wafford et al., Mol. Pharmacol., 1996, 50, 670-678. The procedure will suitably be carried out utilising cultures of stably transfected eukaryotic cells, typically of stably transfected mouse Ltk fibroblast cells.The compounds according to the present invention exhibit anxiolytic activity, as demonstrated by a positive response in the elevated plus maze and conditioned suppression of drinking tests (cf. Dawson et al., Psychopharmacology, 1995, 121, 109-117). Moreover, the compounds ofthe invention are substantially non-sedating, as confirmed by an appropriate result obtained from the response sensitivity (chain-pulling) test (cf. Bayley et al., J. Psychopharmacol., 1996, 10, 206-213).The compounds according to the present invention may also exhibit anticonvulsant activity. This can be demonstrated by the ability to block pentylenetetrazole-induced seizures in rats and mice, following a protocol analogous to that described by Bristow et al. in J. Pharmacol. Exp. Ther., 1996, 279, 492-501.Since they elicit behavioural effects, the compounds of the invention plainly are brain-penetrant; in other words, these compounds are capable of crossing the so-called "blood-brain barrier". Advantageously, the compounds of the invention are capable of exerting their beneficial therapeutic action following administration by the oral route.The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional table ting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosageforms such as tablets, pills and capsules. This solid pre formulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.In the treatment of anxiety, a suitable dosage level is about 0.01 to 250 mg / kg per day, preferably about 0.05 to 100 mg / kg per day, and especially about 0.05 to 5 mg / kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.The compounds in accordance with the present invention may conveniently be prepared by the processes described in the accompanying Examples.Four anhydrous polymorphs, two solvates and a dihydrate of 7-(l,l-dimethylethyl)-6-(2-ethyl-2i / -l,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-l,2,4-triazolo[4,3-6]pyridazine have been synthesised and characterised. All the polymorphs and solvates revert to the most thermodynamically stable form, polymorph A (for formation and characterisation see Example 3), after stirring as a suspension in water. A dihydrate of polymorph A is stable, but only at elevated humidities.The compounds in accordance with this invention potently inhibit the binding of [3HJ-flumazenil to the benzodiazepine binding site of human GABAa receptors containing the a2 or a3 subunit stably expressed in Ltk" cells.Reagents• Phosphate buffered saline (PBS).• Assay buffer: 10 mM KH2PO4, 100 mM KC1, pH 7.4 at room temperature.• [3H]-Flumazenil (18 nM for alp3y2 cells; 18 nM for a2p3y2 cells; 10 nM for a3p3y2 cells) in assay buffer.• Flunitrazepam 100 (aM in assay buffer.• Cells resuspended in assay buffer (1 tray to 10 ml).Harvesting CellsSupernatant is removed from cells. PBS (approximately 20 ml) is added. The cells are scraped and placed in a 50 ml centrifuge tube. The procedure is repeated with a further 10 ml of PBS to ensure that most of the cells are removed. The cells are pelleted by centrifuging for 20 min at 3000 rpm in a benchtop centrifuge, and then frozen if desired. The pellets are resuspended in 10 ml of buffer per tray (25 cm x 25 cm) of cells.AssayCan be carried out in deep 96-well plates or in tubes. Each tube contains:• 300 of assay buffer.• 50 (J.1 of [3H]-flumazenil (final concentration for al(33y2: 1.8 nM; for a2p3y2: 1.8 nM; for a3p3y2: 1.0 nM).• 50 jj.1 of buffer or solvent carrier (e.g. 10% DMSO) if compounds are dissolved in 10% DMSO (total); test compound or flunitrazepam (to determine non-specific binding), 10 (iM final concentration.• 100 jj.1 of cells.Assays are incubated for 1 hour at 40°C, then filtered using either a Tomtec or Brandel cell harvester onto GF / B filters followed by 3 x 3 ml washes with ice cold assay buffer. Filters are dried and counted by liquid scintillation counting. Expected values for total binding are 3000-4000 dpm for total counts and less than 200 dpm for non-specific binding if using liquid scintillation counting, or 1500-2000 dpm for total counts and less than 200 dpm for non-specific binding if counting with meltilex solid scintillant. Binding parameters are determined by non-linear least squares regression analysis, from which the inhibition constant Ki can be calculated for each test compound.The compounds of the accompanying Examples were tested in the above assay, and were found to possess a Ki value for displacement of [3H]-flumazenil from the a2 and / or a3 subunit of the human GABAa receptor of less than 1 nM.EXAMPLE 17-(l,l-Dimethvlethvl)-6-(2-ethvl-2H-1.2.4-triazol-3-vlmethoxv)-3-(2-fluorophenvD-1,2,4-triazolo[4,3-blpyridazinea) 3,6-Dichloro-4-(l,l-dimethylethvl)pvridazineConcentrated sulphuric acid (53.6 ml, 1.0 mol) was added carefully to a stirred suspension of 3,6-dichloropyridazine (50.0 g, 0.34 mol) in water (1.25 1). This mixture was then heated to 70°C (internal temperature)before the addition of trimethylacetic acid (47.5 ml, 0.41 mol). A solution of silver nitrate (11.4 g, 0.07 mol) in water (20 ml) was then added over approximately one minute. This caused the reaction mixture to become milky in appearance. A solution of ammonium persulphate (230 g, 1.0 mol) in water (0.63 1) was then added over 20-30 minutes. The internal temperature rose to approximately 85°C. During the addition the product formed as a sticky precipitate. Upon complete addition the reaction was stirred for an additional 10 minutes, then allowed to cool to room temperature. The mixture was then poured onto ice and basified with concentrated aqueous ammonia, with the addition of more ice as required to keep the temperature below 10°C. The aqueous was extracted with dichloromethane (3 x 300 ml). The combined extracts were dried (MgSC>4), filtered and evaporated to give 55.8 g of crude product as an oil. This was purified by silica gel chromatography using 0-15% ethyl acetate in hexane as eluent to give 37.31 g (53%) of the desired compound. Data for the title compound: W NMR (360 MHz, d6-DMSO) 6 1.50 (9H, s), 7.48 (1H, s); MS (ES+) m / e 205 [MH]+, 207 [MH]+.b) 6-Chloro-7-(l.l-dimethvlethvD-3-(2-fluorophenvl)-1.2.4-triazolor4.3-61pyridazineA mixture of 3,6-dichloro-4-(l,l-dimethylethyl)pyridazine (20 g, 0.097 mol), 2-fluorobenzhydrazide (22.6 g, 0.145 mol) and triethylamine hydrochloride (20 g, 0.0145 mol) in dioxan (1.2 1) was stirred and heated at reflux under a stream of nitrogen for 4 days. Upon cooling the volatiles were removed in vacuo and the residue was triturated with dichloromethane (200 ml), filtered and concentrated under vacuum. The residue was purified by chromatography on silica gel eluting with 0%-»25% ethyl acetate / dichloromethane to give the title compound (12.95 g, 44%) as a white solid. Data for the title compound: JH NMR (360 MHz, CDCI3) 8 1.57 (9H, s), 7.26-7.35 (2H, m), 7.53-7.60 (1H, m), 7.89-7.93 (1H, m), 8.17 (1H, s); MS (ES+) m / e 305 [MH]+, 307 [MH]+.c) (2-Ethvl-2ijr-1.2.4-triazol-3-vDmethanolTo a solution of 1,2,4-triazole (10 g, 0.145 mol) in DMF (150 ml) at room temperature was added sodium hydride (6.4 g of a 60% disp. in oil, 0.16 mol) in portions over 15 min. When the addition was complete, the reaction mixture was allowed to cool to room temperature, then cooled in an ice-bath and iodoethane (14 ml, 0.174 mol) added dropwise over 10 min. The reaction mixture was allowed to warm to room temperaure and after stirring for 3 h the solvents were removed under high vacuum to leave a residue which was partitioned between water (300 ml) and ethyl acetate (3 x 300 ml). The combined organic layers were washed with saturated brine and dried (MgS04), filtered and concentrated under vacuum to leave an oily residue which was purified by distillation (120°C @ -20 mmHg) to give 1 -ethyl-1,2,4-triazole contaminated with -15% DMF (2.4 g). The crude product (2.4 g, 0.025 mol) was dissolved in dry THF (35 ml), cooled to -40°C and ^-butyllithium (16.2 ml of a 1.6 M solution in hexane, 0.026 mol) was added slowly over 20 min keeping the temperature constant. DMF (2.03 ml, 0.026 mol) was then added and after 15 min the reaction mixture was allowed to warm slowly to room temperature over 2 h. To the reaction mixture was added methanol (20 ml) followed by sodium borohydride (1 g, 0.026 mol) and the solution was allowed to stir for 14 h. The solvents were removed under vacuum and the residue was partitioned between brine (50 ml) and dichloromethane (6 x 50 ml). The combined organic layers were dried (MgS04), filtered and concentrated under vacuum to leave a residue which was purified by silica gel chromatography using 0-5% methanol in dichlorometane as eluent to give the title compound as an off-white solid (0.5 g, 3%). Data for the title compound: *H NMR (250 MHz, CDCI3) 5 1.48 (3H, t, J = 7.3 Hz), 4.25 (2H, q, J = 7.3 Hz), 4.75 (2H, s), 5.14 (1H, br s), 7.78 (1H, s).d) 7-a.l-Dimethvlethvl)-6-(,2-ethvl-2i / -1.2.4-triazol-3-vlmethoxvV3-(2-fluorophenvl)-1,2,4-triazolo [4,3- blp yridazineTo a solution of (2-ethyl-2#-l,2,4-triazol-3-yl)methanol (0.094 g, 0.74 mmol) and 6-chloro-7-(l,l-dimethylethyl)-3-(2-fluorophenyl)-l,2,4-triazolo[4,3-6]pyridazine (0.15 g, 0.49 mmol) in DMF (10 ml) was added sodium hydride (0.024 g of a 60% dispersion in oil, 1.1 mol eq.) and the reaction mixture was stirred at room temperature for 30 minutes. After this time, the reaction mixture was diluted with water (80 ml) and the solid that precipitated was collected by filtration and washed several times with water in the sinter funnel. The solid was recrystallised from ethyl acetate / hexane to give pure title compound (0.085 g, 44%). Data for the title compound: NMR (250 MHz, CDCI3) 6 1.40-1.47 (12H, m), 4.14 (2H, t, J = 7.3 Hz), 5.26 (2H, s), 7.26-7.38 (2H, m), 7.53-7.58 (1H, m), 7.86-7.90 (1H, m), 7.93 (1H, s), 7.99 (1H, s); MS (ES+) m / e 396 [MH]+. Anal. Found C, 61.02; H, 5.45; N, 24.75%. C20H22FN7O requires C, 60.75; H, 5.61; N, 24.79%.EXAMPLE 27-(l.l-Dimethvlethvl)-6-(2-ethvl-2H-1.2.4-triazol-3-vlmethoxv)-3-(2-fluorophenvl)-l,2.4-triazolo[4,3-blpyridazine: Alternative Synthetic Routea) 3.6-Dichloro-4-(l,l-dimethylethvl)pyridazineA mixture of dichloropyridazine (100 g, 0.67 mol), trimethylacetic acid (96 g, 0.94 mol) and water (800 ml) in a 10 1 flask with overhead stirring was warmed to 55°C resulting in a two-phase solution. A solution of AgNC>3 (11.4 g, 0.134 mol) in water (125 ml) was added in one portion resulting in an opaque solution. Trifluoroacetic acid (10.3 ml, 0.134 mol) was added in one portion. Ammonium persulfate (245 g, 1.07 mol) was dissolved in water (500 ml) and added dropwise to the suspension over 45-60 min resulting in an exotherm (typically temperature increases tobetween 75-80°C and can be controlled by rate of persulfate addition). The temperature was maintained at 75°C for a further 1 h and then cooled to room temperature. The reaction mixture was extracted with isobutyl alcohol (11) and the aqueous layer discarded. The organic layer was washed with water (250 ml) and the aqueous cut discarded. HPLC assay yield is 134 g (97%). The isobutyl alcohol solution was used as is in the next step.b) 6-Chloro-5-(l,l-dimethylethvl)pvridazin-3-vlhvdrazineHydrazine hydrate (95 ml, 1.95 mol) was added to the isobutylalcohol solution from step a in a 3 1 flask and heated at 90°C for 20 h. The reaction mixture was cooled to room temperature and the lower aqueous layer discarded. The reaction mixture was washed with water (450 ml) and the aqueous cut discarded. The reaction mixture was distilled under reduced pressure until the product started to crystallise and then 1-methyl-2-pyrrolidinone (NMP) (550 ml) was added. Distillation was continued to remove the last of the isobutyl alcohol. The solution was used as is in the next step.c) 6-Chloro-7-(l.l-dimethvlethvD-3-(2-fluorophenvl)-1.2.4-triazolof4.3-6]pvridazine2-Fluorobenzoyl chloride (103 g, 0.65 mol) was added dropwise to the cooled (0°C) NMP solution from step b maintaining the internal temperature <5°C. After the addition the reaction mixture was heated at 130°C for 2 h. The reaction mixture was cooled to room temperature which resulted in the crystallisation of the product. Water (1.3 1) was added dropwise over 30 min. The slurry was cooled to 10°C and the solid isolated by filtration, then dried under reduced pressure to afford product (145 g, 71% yield from 3,6-dichloropyridazine).d) 1 -Ethvl-1.2,4-triazole1,2,4-Triazole (100.0 g, 1.45 mol) in anhydrous THF (950 ml) was cooled to 0°C and l,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (220 g, 1.45 mol) was added in one portion. The reaction mixture was stirred for 30 min until complete dissolution was observed. Whilst maintaining the ice / water cooling bath, iodoethane (317 g, 2.03 mol) was added dropwise over a 15 min period resulting in an internal temperature rise to 30°C. The reaction was stirred at room temperature for 16 h, after which the DBU hydroiodide was removed by filtration. The filtrate solution was used as is in the next step.e) (2-Ethvl-2i7-1.2.4-triazol-3-vl)methanolThe stirred solution from the preceding step was cooled to -75°C internal temperature in a solid CO^acetone slurry bath. Hexyllithium (458 ml of 33% solution in hexanes) was added dropwise over 25 min keeping the internal temperature below -55°C. The reaction mixture was aged for 30 min (back to -75°C) and then neat DMF (108 ml, 1.39 mol) was added dropwise over 10 min maintaining internal temperature below -60°C. The reaction mixture was aged at -70°C for 90 min before the cooling bath was removed and the reaction mixture allowed to warm to 0°C over 30 min. Industrial methylated spirits (340 ml) was added over 10 min. Sodium borohydride (26.3 g, 0.695 mol) was then added portionwise maintaining internal temperature below 6°C. After the addition the reaction mixture was allowed to warm to room temperature and stirred for 1 h at that temperature. The reaction was quenched by the careful addition of 2M H2SO4 (200 ml) and then stirred at room temperature for 20 h. The reaction mixture was concentrated to 675 ml and sodium sulfate (135 g) was added in one portion. The reaction mixture was warmed to 35°C and stirred for 15 min. The solution was extracted with warm (45°C) isobutyl alcohol (2 x 675 ml). The combined organic fractions were concentrated under reduced pressure 450 ml at which point the productcrystallised. Heptane (1.125 1) was added and the slurry concentrated under reduced pressure to remove most of the isobutyl alcohol. Heptane was added to give a final slurry volume of 680 ml. After cooling to 0°C, filtration gave the title compound (137 g, 74% from 1,2,4-triazole).f) 7-(l.l-Dimethvlethvl)-6-(2-ethvl-2iJ-1.2.4-triazol-3-vlmethoxv')-3-(2-fluorophenvl) -1.2.4-triazolo [4,3- blp vridazineMethod A6-Chloro-7-(l,l-dimethylethyl)-3-(2-fluorophenyl)-l,2,4-triazolo[4,3-6]pyridazine (255 g, 0.819 mol), (2-ethyl-2i7-l,2,4-triazol-3-yl)methanol (125 g, 0.983 mol) and cesium carbonate (640 g, 1.966 mol) were charged to a 10 1 flask equipped with an overhead stirrer. Dimethyl sulfoxide (2.5 1) was added in one portion and the reaction mixture stirred at room temperature for 20 h. The product had crystallised. The reaction mixture was maintained at <25°C whilst water (5 1) was added dropwise over 45 min to the stirred suspension. After cooling to 10°C, the product was isolated by filtration and the cake washed with water (1.75 1). Drying at 50°C in vacuo gave the title compound (317 g, 98%) as a white solid.Method B6-Chloro-7-(l,l-dimethylethyl)-3-(2-fluorophenyl)-l,2,4-triazolo[4,3-b]pyridazine (10 g, 32.12 mmol) and (2-ethyl-2£T-l,2,4-triazol-3-yl)methanol (5.01 g, 38.55 mmol) were charged to a 500 ml flask equipped with an overhead stirrer. NMP (100 ml) was added in one portion and the reaction mixture stirred until complete dissolution was achieved. The reaction mixture was cooled to 0°C and 48% w / w sodium hydroxide solution (4.02 g, 46 mmol) was added in one portion. After stirring for 1 h at 0°C, the product had crystallised. Water (100 ml) was added dropwise over 15 min and the slurry aged for 30 min. The product was isolated byfiltration and the cake washed with water (100 ml). Drying at 50°C in vacuo gave the title compound (12.50 g, 98%) as a white solid.EXAMPLE 3Formation and Characterisation of Polymorphs and Solvates of 7-(l.l-dimethvlethvl)-6-(2-ethvl-2jJ-1.2.4-triazol-3-vlmethoxv)-3-(2-fluorophenvl) 1,2,4-triazolo [4.3-b)vyridazine7-(l, l-Dimethylethyl)-6-(2-ethyl-2 / 7-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-l,2,4-triazolo[4,3-6]pyridazine (hereinafter referred to as Compound IA) was recrystallised from a selection of organic solvents and the resultant solids were dried in vacuo overnight at 60°C unless otherwise stated. Each batch was then characterised by optical microscopy, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and X-ray powder diffraction (XRPD). Four distinct anhydrous polymorphs, a hydrate and two solvates have been characterised, as summarised in Table 1.Table 1: Polymorphs of Compound IAPolymorph APolymorph A consists of irregular or elongated rectangular birefringent crystals. It shows one major endotherm by DSC at ca. 186°C due to melting. In the case of some of the samples prepared this melt displays several events happening within it, typified by shoulders on the melting endotherm. Polymorph A is anhydrous and displays no losses by TGA. It has a unique XRPD diffractogram, typified by two peaks at 29 « 7.3°.Polymorph BPolymorph B consists of irregular or elongated rectangular birefringent crystals. Polymorph B displays one major endotherm by DSC at ca. 181°C due to melting. It is anhydrous and displays no weight loss by TGA. It has a unique XRPD diffractogram.Polymorph CPolymorph C consists of acicular, birefringent crystals. The DSC thermograms of polymorph C show an endotherm at ca. 170°C, an exotherm at ca. 173°C, a small endotherm at ca. 181°C, and an endotherm due to melting at ca. 186°C. No losses are observed by thermogravimetric analysis.Polymorph DPolymorph D consists of acicular birefringent crystals. The XRPD diffractogram of polymorph D is similar in pattern to that of polymorph C. However, significant differences are observed, notably additional peaks at 20 = 9.861, 15.113, 18.015 and 22.224. The DSC trace of polymorph D displays a very broad exotherm at ca. 108°C, followed by an endotherm and exotherm at 170°C and 173°C, as for polymorph C. The major melting is observed at ca. 181°C, and several events are seen to occur within the melting endotherm, with minor melting at 186°C. No losses are observed by TGA.Methanol SolvateThe DSC thermogram of the methanol solvate shows one endotherm at ca. 157°C due to loss of methanol, and one endotherm at 186°C due to melting. A gradual loss is observed by TGA up to ca. 150°C, at which point a step loss is observed, coincident with the endotherm observed by DSC. This step loss is in some instances composed of more than one event,and the amount varies among recrystallised samples and does not appear to correspond to a stoichiometric solvate. However, methanol vapour sorption studies on polymorph A show the presence of a distinct hemisolvate. The XRPD diffractogram of the solvate is unique.Ethanol SolvateThe ethanol solvate is typified by its DSC thermogram which shows one endotherm at ca. 111°C due to loss of ethanol, and an endotherm at ca. 186°C due to melting. TGA shows the loss to be variable in different recrystallised samples, between ca. 4 and 6.5%, and does not correspond to a stoichiometric solvate. The XRPD diffractogram is unique.Hydrate of Polymorph AFigure 1 shows the adsorption / desorption isotherm of Compound IA polymorph A at 25°C. These moisture vapour sorption studies show formation of a dihydrate above 80% relative humidity (RH) at 25°C. Hysteresis indicative of hydrate formation is seen to occur, with desorption occurring below ca. 60% RH.Figure 2 shows side-by-side XRPD diffractograms of anhydrous Compound IA polymorph A and of the dihydrate of polymorph A. The XRPD diffractogram of the dihydrate, obtained on a wetted sample of polymorph A, demonstrates the distinct differences observed between the two forms. The major changes in diffraction can be seen to be loss of the peak at 20 = 11.2°, and the appearance of two major peaks at 20 = 11.9° and 12.3°.Conversion of Compound IA Polymorphs to Polymorph AOn slurrying in water all of the polymorphs and solvates decribed above convert to polymorph A over a period of 1-4 days, indicating that this is the most stable form at room temperature. This conversion is slowdue to the low aqueous solubility of Compound IA in relation to the large excess of solid compound slurried.X-Rav Powder Diffraction DataFigure 3 shows side-by-side XRPD diffractograms of anhydrous Compound IA polymorphs A, B, C and D, of the methanol and ethanol solvates, and of the dihydrate of polymorph A. Numerical data associated therewith are presented below.Compound IA Polymorph A: X-Ray Powder Diffraction DataCompound IA Polymorph B: X-Ray Powder Diffraction DataCompound IA Polymorph C: X-Ray Powder Diffraction DataCompound IA Polymorph D: X-Ray Powder Diffraction DataCompound IA Methanol Solvate: X-Ray Powder Diffraction DataCompound IA Ethanol Solvate: X-Ray Powder Diffraction DataCompound IA Hydrate of Polymorph A: X-Ray Powder Diffraction DataPREPARATIVE EXAMPLE A7-Cvclobutvl-3-(3.5-difluorophenvl)-6-(2-methvl-2 / f-1.2.4-triazol-3-vlmethoxv)-1, 2,4-triazolo [4,3-felpyridazinea) 3,6-Dichloro-4-cvciobutvlpyridazineConcentrated sulphuric acid (53.6 ml, 1.0 mol) was added carefully to a stirred suspension of 3,6-dichloropyridazine (50.0 g, 0.34 mol) in water (1.25 1). This mixture was then heated to 70°C (internal temperature) before the addition of cyclobutane carboxylic acid (35.3 ml, 0.37 mol). A solution of silver nitrate (11.4 g, 0.07 mol) in water (20 ml) was then added over approximately one minute. This caused the reaction mixture to become milky in appearance. A solution of ammonium persulphate (230 g, 1.0 mol) in water (0.63 1) was then added over 20-30 minutes. The internal temperature rose to approximately 85°C. During the addition the product formed as a sticky precipitate. Upon complete addition the reaction was stirred for an additional 5 minutes, then allowed to cool to room temperature. The mixture was then poured onto ice and basified with concentrated aqueous ammonia, with the addition of more ice as required to keep the temperature below 10°C. The aqueous was extracted with dichloromethane (x3). The combined extracts were dried (MgS04), filtered and evaporated to give the title compound (55.7 g, 82%) as an oil. *H nmr (CDCI3) indicated contamination with approximately 5% of the 4,5-dicyclobutyl compound. However, this material was used without further purification. Data for the title compound: *H NMR (360 MHz, d6-DMSO) 5 1.79-1.90 (1H, m), 2.00-2.09 (1H, m), 2.18-2.30 (2H, m), 2.33-2.40 (2H, m), 3.63-3.72 (1H, m), 7.95 (1H, s); MS (ES+) m / e 203 [MH]+, 205 [MH]+, 207 [MH]+.b) 3-Chloro-4-cvclobutvl-6-hydrazinopvridazine3,6-Dichloro-4-cyclobutylpyridazine (10 g, 0.049 mol) and hydrazinehydrate (14 ml, 0.30 mol) were heated at reflux in dioxan (125 ml) for 24 hours. Upon cooling the desired isomer crystallized from the reaction and was collected by filtration (4.8 g, 49%). *H NMR (250 MHz, de-DMSO) 5 1.68-1.86 (1H, m), 2.00-2.11 (3H, m), 2.29-2.38 (2H, m), 3.52-3.61 (1H, m), 4.35 (2H, br), 6.99 (1H, s), 8.06 (1H, br); MS (ES+) m / e 198 [MH]+, 200 [MH]+.c) A^-(6-Chloro-5-cvclobutvlpvridazin-3-vl)-iV-(3.5-difluoro-benzvlidene)hydrazine3-Chloro-4-cyclobutyl-6-hydrazinopyridazine (0.502 g, 2.53 mmol) and 3,5-difluorobenzaldehyde (285 ml, 2.78 mmol) were stirred in 0.2M hydrochloric acid (10 ml) for 2 hours. This product was then collected by filtration and dried (0.81 g, 99%). MS (ES+) 323 [MH]+, 325 [MH]+.d) 6-Chloro-7-cvclobutvl-3-(3.5-difluorophenvD-1.2.4-triazolor4.3-6]pvridazineFerric chloride (3.423 g, 12.66 mmol) in ethanol (15 ml) was added dropwise to a solution of A^(6-chloro-5-cyclobutylpyridazin-3-yl)-iV-(3,5-difluorobenzylidene)hydrazine (0.816 g, 2.53 mmol) in ethanol (35 ml) and heated at 70°C. After 3 hours the reaction mixture was partitioned between dichloromethane (250 ml) and brine (250 ml). The organic phase was dried (MgSCU), filtered and evaporated. The residue was purified by chromatography on silica gel, eluting with ethyl acetate-hexane mixtures to afford the title pyridazine (0.51 g, 63%). *H NMR (250 MHz, CDCI3) 1.84-2.08 (1H, m), 2.08-2.36 (3H, m), 2.42-2.68 (2H, m), 3.65-3.87 (1H, m), 6.88-7.06 (1H, m), 8.01 (1H, s), 8.04-8.21 (2H, m). MS (ES+) 321 [MH]+, 323 [MH]+.e) 7-Cvclobutvl-3-(3,5-difluorophenyl)-6-(2-methyl-2i / -1.2.4-triazol-3-vlmethoxv)-1,2,4-triazolo [4.3-blp vridazineTo a solution of (2-methyl-2#-l,2,4-triazol-3-yl)methanol (0.099 g, 0.879 mmol) (prepared using the conditions described in EP-A-421210) in DMF (15 ml) was added sodium hydride (0.035 g of a 60% dispersion in oil, 1.1 mol eq.) and the reaction mixture was stirred at room temperature for 30 minutes. After this time the foregoing product (0.256 g, 0.799 mmol) was added as a solution in DMF (15 ml) and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with water (100 ml) and the aqueous extracted with dichloromethane (4 x 100 ml). The combined extracts were dried (Na2SC>4), filtered and evaporated. The residue was purified by chromatography on silica gel using 3% MeOH in dichloromethane as eluent to give the required product (0.120 g, 38%). NMR (360 MHz, CDCI3) 8 1.86-2.02 (1H, m), 2.08-2.25 (3H, m), 2.32-2.46 (2H, m), 3.56-3.70 (1H, m), 4.01 (3H, s), 5.64 (2H, s), 6.92-7.01 (1H, m), 7.90 (1H, s), 7.94 (1H, s), 8.03-8.12 (2H, m); MS (ES+) m / e 398 [MH]+.EXAMPLE 47-Cvclobutvl-3-(2.6-difluorophenvl)-6-(2-methvl-2 / / -1.2.4-triazol-3-vlmethoxy)-1,2.4-triazolo \4,3- b]p vridazineThis compound was prepared using the procedures described in Preparative Example A, using 2,6-difluorobenzaldehyde instead of 3,5-difluorobenzaldehyde in Step c). Data for the title compound: XH NMR (360 MHz, CDCI3) 8 1.86-1.96 (1H, m), 2.04-2.24 (3H, m), 2.30-2.42 (2H, m), 3.56-3.68 (1H, m), 3.84 (3H, s), 5.42 (2H, s), 7.08-7.16 (2H, m), 7.55-7.60 (1H, m), 7.88 (2H, m); MS (ES+) m / e 398 [MH]+.

Claims

1. 7-(l,l-Dimethylethyl)-6-(2-ethyl-2H-l,2,4-triazol-3ylmethoxy)-3-(2-fluorophenyl)-l,2,4-triazolo[4,3-&]pyridazine.

2. Polymorph A of 7-(1, l-dimethylethyl)-6-(2-ethyl-2 / 7-1,2,45 triazol-3-ylmethoxy)-3-(2-fluorophenyl)-l,2,4-triazolo[4,3-6]pyridazine as characterised herein.

3. A pharmaceutical composition comprising 7-(1,1dimethylethyl)-6-(2-ethyl-2 / 7-l,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl) l,2,4-triazolo[4,3-6]pyridazine in association with a pharmaceutically 10 acceptable carrier.

4. The use of7-(l,l-dimethylethyl)-6-(2-ethyl-27 / -l,2,4-triazol-3ylmethoxy)-3-(2-fluorophenyl)-l,2,4-triazolo[4,3-6]pyridazine for the manufacture of a medicament for the treatment and / or prevention of anxiety.

155. A process for the preparation of 7-(l,l-dimethylethyl)-6-(2ethyl-2 / 7-l,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-l,2,4-triazolo[4,36]pyridazine, which comprises reacting 6-chloro-7-(l,l-dimethylethyl)-3-(2fluorophenyl)-l,2,4-triazolo[4,3-6]pyridazine and (2-ethyl-27 / -l,2,4-triazol3-yl)methanol in l-methyl-2-pyrrolidinone, in the presence of sodium 20 hydroxide, at a temperature in the region of 0°C. PI 99002465 - 30 6. 7-Cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-27 / -l,2,4triazol-3-ylmethoxy)-1,2,4-triazolo [4,3- hjpyridazine.

7. A pharmaceutical composition comprising 7-cyclobutyl-3-(2,6difluorophenyl)-6-(2-methyl-27 / -1,2,4-triazol-3-ylmethoxy)-l,2,45 triazolo[4,3-6]pyridazine in association with a pharmaceutically acceptable carrier.

8. The use of 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-27 / l,2,4-triazol-3-ylmethoxy)-l,2,4-triazolo[4,3-6]pyridazine for the manufacture of a medicament for the treatment and / or prevention of 10 anxiety.